195 results on '"Tombal, B"'
Search Results
2. Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
3. Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
4. 1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
5. 1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
6. Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study
7. 173P Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
8. Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study
9. 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
10. 1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study
11. 1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial
12. 1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial
13. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
14. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
15. Sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study
16. Characterization of T cells during BCG therapy for NMIBC
17. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
18. 622P Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)
19. LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
20. 621P Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study
21. 614P Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance
22. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
23. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
24. 629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
25. Variations in the exposure to sunitinib with immediate and deferred cytoreductive nephrectomy (CN). A post-hoc analysis of the randomized controlled EORTC SURTIME trial
26. Risk of death from prostate cancer in patients with biopsy Gleason score 6 and additional clinical high-risk features: A European multi-institutional study
27. Stratification of high-risk prostate cancer with positive lymph nodes into prognostic groups to predict cancer related death: A European multi-institutional study
28. Impact of Enzalutamide (ENZA) on Patient-Reported Outcomes (PROs) in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients with no/low urinary symptoms at baseline: Results from the ARCHES study
29. PCN278 CORRELATION BETWEEN THE BRIEF FATIGUE INVENTORY (BFI) AND FUNCTIONAL ASSESSMENT OF CANCER THERAPY–PROSTATE (FACT-P) TO MEASURE FATIGUE IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
30. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
31. Plasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial
32. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
33. CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
34. A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy
35. Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI
36. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Long-term overall survival and safety analyses of the phase 3 PREVAIL study
37. Metabolic syndrome components and prostatic hyperplasia among diabetic and non-diabetic men in the Eastern DR Congo: A cross-sectional study
38. Anthropometric and cardiometabolic correlates of prostate volume among diabetic and non-diabetic subjects in South-Kivu
39. Association entre la qualité de vie liée à la santé (qdv) et les signes cliniques du cancer de prostate résistant à la castration non métastatique (cprcnm) : résultats de l’étude prosper
40. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
41. Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)
42. Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE
43. ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
44. Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study
45. Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment
46. Rare cas de perforation urétérale compliquant le vissage pédiculaire par chirurgie minimale invasive
47. REASSURE observational study of radium-223 (Ra-223): First interim results by prior/concomitant treatment (Tx) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) enrolled in Europe
48. Gleason score 6 prostate cancer is not always harmless
49. Patient-reported outcome measures in men with non-metastatic castration-resistant prostate cancer: Baseline data from the PROSPER trial
50. Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.